Salix Pharmaceuticals, Ltd.
1700 Perimeter Park Drive
370 articles with Salix Pharmaceuticals, Ltd.
Salix To Highlight New Data Across Its Portfolio Of Products At Digestive Disease Week 2020 Virtual Meeting
Bausch Health Companies Inc. and Salix Pharmaceuticals announced that fourteen new scientific posters featuring research and data spanning Salix's GI portfolio – including rifaximin, plecanatide, methylnaltrexone bromide and PEG-3350, electrolytes and ascorbate for oral solution – will be accessible on Digestive Disease Week®'s ePosters and ePapers free, online portal beginning Saturday, May 2, 2020.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
Additional Use Patent Covering IBS Strengthens Patent Portfolio
Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. regarding APRISO® extended-release capsules 0.375g.
Salix Pharmaceuticals Pledges Annual $100,000 Scholarship Program To Outstanding Students Living with GI Disease
Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, today announced that it will launch the Salix Gastrointestinal Health Scholars Program,
Salix Pharmaceuticals Marks 30-Year Anniversary With Largest Showing Of Data At Digestive Disease Week
Breadth of Data Reinforces Decades of Commitment to Healthcare Providers and Patients
Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
Investigational Oral Compound to Strengthen Salix's Expanding Pipeline
Salix Launches National Initiatives Aimed At Improving Recognition Of IBS Symptoms, Early Diagnosis And Treatment
In Honor of April's IBS Awareness Month, Efforts Highlight Advances in Research
Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis
Investigational Treatment Demonstrated Promising Results in Preclinical Studies
Salix Announces Poster Presentations for Overt Hepatic Encephalopathy and Opioid-Induced Constipation at Hospital Medicine 2019
Salix Pharmaceuticals will present scientific research, including data from three abstracts at Hospital Medicine 2019, the annual conference of the Society of Hospital Medicine, being held in National Harbor, Md., March 24-27, 2019.
Salix Announces Two Methylnaltrexone Poster Presentations for Opioid-Induced Constipation at the Annual Assembly of the American Academy of Hospice and Palliative Medicine and Hospice and Palliative Nurses Association
The complete list of poster presentations from Salix will be presented on Wednesday, March 13, 6:30-7:30 pm and Thursday, March 14, 6:00-7:00 pm Eastern Time
ZAXINE (rifaximin) - Now Indicated in Canada for Patients with Irritable Bowel Syndrome with Diarrhea (IBS-D)1,2
Lupin Pharma Canada is pleased to announce the approval from Health Canada for ZAXINE® 550 mg (rifaximin) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease
Salix Pharmaceuticals, Ltd. announced it has entered into an amendment to its existing license agreement with Alfasigma S.p.A. ("Alfasigma") to initiate a late-stage clinical program to study an investigational formulation of rifaximin in patients with postoperative Crohn's disease, an area of unmet medical need.
Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting
Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Bausch Health Companies Inc.
Salix Pharmaceuticals, Ltd., one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today issued the following statement regarding the successful resolution of the legacy investigation with the Securities and Exchange Commission (SEC).
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)
Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure
US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference
Product Theater, Three Posters and Oral Poster Presentation to be Featured
First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription
Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center
Research Led by Dr. Mark Pimentel's Lab Will Explore the Role of the Microbiome in the Treatment of Gastrointestinal (GI) Disorders